Oppenheimer initiated coverage on enGene Holdings with a new price target
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer initiated coverage of enGene Holdings with a rating of Outperform and set a new price target of $30.00